Evidence map›Paper›PMID 29482216›Full record

ArticleJAMA neurology2018

Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis.

Angela Rosenbohm, Gabriele Nagel, Raphael S Peter, Torben Brehme, Wolfgang Koenig, Luc Dupuis, Dietrich Rothenbacher, Albert C Ludolph, ALS Registry Study Group

Open access · bronzeAbstract read
In one paragraph

Article in JAMA neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The links between diabetes mellitus and amyotrophic lateral sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Angela RosenbohmDepartment of Neurology, University of Ulm, Ulm, Germany.
Gabriele NagelInstitute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
Raphael S PeterInstitute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
Torben BrehmeInstitute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
Wolfgang KoenigDepartment of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany.
Luc DupuisInstitut National de la Santé et de la Récherche Médicale Unité 1118, Université de Strasbourg, Strasbourg, France.
Dietrich RothenbacherInstitute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
Albert C LudolphDepartment of Neurology, University of Ulm, Ulm, Germany.
ALS Registry Study Group
Universität Ulm · DEDeutsches Herzzentrum München · DEInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Knowledge about the metabolic states of patients with amyotrophic lateral sclerosis (ALS) may provide a therapeutic approach. Objective: To investigate the association between the onset and prognosis of ALS and serum retinol-binding protein 4 (RBP4) concentration as a biomarker for insulin resistance and vitamin A metabolism. Design, Setting, and Participants: Case-control design for risk factors of ALS; cohort design for prognostic factors within ALS cases. Between October 1, 2010, and June 30, 2014, a population-based case-control study with randomly selected controls was established based on the ALS Registry Swabia in southern Germany, with a target population of 8.4 million inhabitants. Response rates were 64.8% among the cases and 18.7% among the controls. The dates of analysis were April 2016 to May 2017. Main Outcomes and Measures: Serum samples were measured for RBP4. Information on covariates was assessed by an interview-based standardized questionnaire. Main outcomes and measures were adjusted odds ratios for risk of ALS associated with serum RBP4 concentration, as well as time to death associated with RBP4 concentration at baseline in ALS cases only. Conditional logistic regression was applied to calculate multivariable odds ratios for risk of ALS. Survival models were used in cases only to appraise their prognostic value. Results: Data from 289 patients with ALS (mean [SD] age, 65.7 [10.5] years; 172 [59.5%] male) and 504 controls (mean [SD] age, 66.3 [9.8] years; 299 [59.3%] male) were included in the case-control study. Compared with controls, ALS cases were characterized by lower body mass index, less educational attainment, smoking, light occupational work intensity, and self-reported diabetes. The median serum RBP4 concentration was lower in ALS cases than in controls (54.0 vs 59.5 mg/L). In the multivariable model, increasing RBP4 concentration was associated with reduced odds for ALS (top vs bottom quartile odds ratio, 0.36; 95% CI, 0.22-0.59; P for trend <.001), which persisted after further adjustment for renal function and for leptin and adiponectin. Among 279 ALS cases during a median follow-up of 14.5 months, 104 died (mean [SD] age, 68.9 [10.3] years; 56 [53.9%] male). In this ALS cohort, an inverse association was found between serum RBP4 concentration as a continuous measure and survival. Conclusions and Relevance: RBP4 was inversely related to risk for and prognosis of ALS, suggesting that vitamin A metabolism or impaired insulin signaling could be involved. Further research, including a prospective design and other biological markers, is necessary to clarify the role of insulin resistance in the pathogenesis of ALS.

Indexed as

AgedAmyotrophic Lateral SclerosisCase-Control StudiesCohort StudiesCommunity Health PlanningFatsFemaleGermanyHumansLogistic ModelsMaleMiddle AgedPrognosisRetinol-Binding Proteins, PlasmaRisk FactorsVitamin AFatsRBP4 protein, humanRetinol-Binding Proteins, PlasmaVitamin A

Identifiers

PMID29482216
PMCPMC5885207
OpenAlexW2793927863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.